

Financial news for TROV dated on 2020-05-07: TrovaGene Q1 EPS \$(0.410) Up From \$(1.020) YoY

Financial news for TROV dated on 2020-05-06: Trovogene Reports Corporate Name Change To Cardiff Oncology, Will Trade Under Ticker 'CRDF'

Financial news for TROV dated on 2020-04-29: 16 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2020-04-28: Trovogene Reports Ongoing Phase 1b/2 Trial For Onvansertib In Combo With FOLFIRI, Avastin Enrolled 12 Patients With 88% Response In 7 Of 8 Evaluable Patients, To-Date 3 Patients With Partial Response, 4 Patients With Stable Disease

Financial news for TROV dated on 2020-04-17: Trovogene Granted \$305K Loan Pursuant To Paycheck Protection Program

Financial news for TROV dated on 2020-03-20: The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

Financial news for TROV dated on 2020-03-19: Stocks That Hit 52-Week Lows On Thursday

Financial news for TROV dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for TROV dated on 2020-03-18: Stocks That Hit 52-Week Lows On Wednesday

Financial news for TROV dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for TROV dated on 2020-03-17: The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment

Financial news for TROV dated on 2020-02-27: TrovaGene Q4 EPS \$(0.51) Up From \$(1.09) YoY, Sales \$93K Up From \$78K YoY

Financial news for TROV dated on 2020-02-14: 77 Biggest Movers From Yesterday

Financial news for TROV dated on 2020-02-13: 58 Stocks Moving In Thursday's Mid-Day Session

Financial news for TROV dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for TROV dated on 2020-02-13: Trovogene Reports Presentation Of Phase 2 Data Showing Ability Of Onvansertib To Overcome Zytiga Resistance

Financial news for TROV dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for TROV dated on 2020-01-29: Trovogene Reports Receives ~\$1.45M From Exercise Of Warrants

Financial news for TROV dated on 2020-01-28: Noble Capital Reinstates Outperform on TrovaGene

Financial news for TROV dated on 2020-01-27: Trovogene Says Onvasertib Demonstrated Effectiveness As Pan-KRAS Inhibitor With Confirmed Tumor Regression And Clinical Benefit Achieved In KRAS-Mutated mCRC Patients

Financial news for TROV dated on 2020-01-22: 98 Biotechnology Stocks Moving In Wednesday's Session

Financial news for TROV dated on 2020-01-21: Trovogene To Present New Clinical Data For Onvansertib In Metastatic KRAS-Mutated Colorectal Cancer At ASCO 2020 Gastrointestinal Cancers Symposium

Financial news for TROV dated on 2019-12-04: Trovogene Announces Data Showing 'Ability of Onvansertib to Rescue Venetoclax-Resistance in Acute Myeloid Leukemia'

Financial news for TROV dated on 2019-12-01: The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More

Financial news for TROV dated on 2019-11-15: 30 Healthcare Stocks Moving In Friday's

Pre-Market Session

Financial news for TROV dated on 2019-11-14: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for TROV dated on 2019-11-14: Benzinga Pro's Top 5 Stocks To Watch For Thurs., Nov. 14, 2019: NVDA, SINA, DDS, TROV, AMRN

Financial news for TROV dated on 2019-11-14: Trovogene Reports Data In Metastatic Prostate Cancer Phase 2 Trial: 72% Of Patients Had Decreases In PSA Levels, 60% Completed 3-Month Treatment

Financial news for TROV dated on 2019-11-07: TrovaGene Q3 EPS \$(0.71) Down From \$(0.18) YoY, Sales \$52K Down From \$88K YoY

Financial news for TROV dated on 2019-10-30: TrovaGene shares are trading higher despite no company-specific news. This could potentially be a rebound after the stock dropped approximately 24% over the past 3 trading sessions.

Financial news for TROV dated on 2019-10-29: 46 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-10-28: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for TROV dated on 2019-10-28: TrovaGene shares are trading lower on continued momentum after the company announced a \$5 million private placement at \$11.814 per share.

Financial news for TROV dated on 2019-10-25: Trovogene Announces \$5M Private Placement at \$1.814/Share

Financial news for TROV dated on 2019-10-25: TrovaGene shares are trading higher despite no company specific news. The stock has rallied approximately 147% over the past 4 days as it continues to trade on higher-than-average volume.

Financial news for TROV dated on 2019-10-24: TrovaGene shares are trading higher despite no company-specific news. The stock is trading on higher-than-average volume.

Financial news for TROV dated on 2019-10-23: TrovaGene shares are trading lower despite no company-specific news. The stock is trading on higher-than-average volume.

Financial news for TROV dated on 2019-10-23: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday, October 23, 2019

Financial news for TROV dated on 2019-10-23: 33 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2019-10-22: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 22, 2019

Financial news for TROV dated on 2019-10-22: Trovogene Highlights Response To Treatment In Patients Enrolled In Phase 1b/2 Trial Of Onvansertib In Combo With FOLFIRI, Avastin: Decreases In Tumor KRAS Mutational Burden In Response To Treatment Was Observed In All 4 Patients Who Completed First Cycle

Financial news for TROV dated on 2019-10-11: Stocks That Hit 52-Week Lows On Friday

Financial news for TROV dated on 2019-10-10: The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO

Financial news for TROV dated on 2019-10-09: Stocks That Hit 52-Week Lows On Wednesday

Financial news for TROV dated on 2019-10-09: The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug

Financial news for TROV dated on 2019-10-02: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for TROV dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for TROV dated on 2019-10-01: A Look At Benzinga Pro's Most-Searched Tickers For October 1, 2019

Financial news for TROV dated on 2019-10-01: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tuesday, October 01, 2019

Financial news for TROV dated on 2019-10-01: Trovogene Presents Overview Of Phase 1b/2 Trial Of Onvansertib In Patients With KRAS-Mutated Metastatic Colorectal Cancer (mCRC) At ESMO

Financial news for TROV dated on 2019-09-30: A Look At Benzinga Pro's Most-Searched Tickers For September 30, 2019

Financial news for TROV dated on 2019-09-30: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday, September 30, 2019

Financial news for TROV dated on 2019-09-30: 18 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for TROV dated on 2019-09-30: Trovogene Highlights Presentation Of Phase 1b/2 Study Of Onvansertib At Society For Medical Oncology Conference

Financial news for TROV dated on 2019-09-27: The Daily Biotech Pulse: ESMO Conference Gets Underway, J&J's Darzalex Snags Another Approval, Kaleido Biosciences CFO To Leave

Financial news for TROV dated on 2019-09-22: The Week Ahead In Biotech: Spotlight On ESMO Conference

Financial news for TROV dated on 2019-09-19: rovogene Announces Completion Of Phase 1b Trial Of Onvansertib In Acute Myeloid Leukemia And Initiation Of Patient Enrollment In Phase 2

Financial news for TROV dated on 2019-09-12: 50 Stocks Moving In Thursday's Mid-Day Session

Financial news for TROV dated on 2019-09-12: 33 Stocks Moving in Thursday's Pre-Market Session

Financial news for TROV dated on 2019-08-27: 50 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-08-26: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for TROV dated on 2019-08-26: A Look At Benzinga Pro's Most-Searched Tickers For August 26, 2019

Financial news for TROV dated on 2019-08-26: Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Monday., August 26, 2019

Financial news for TROV dated on 2019-08-26: Trovogene Highlights Presentation Of Clinical Data From Ongoing Phase 2 Study Of Onvansertib In Metastatic Castration-Resistant Prostate Cancer

Financial news for TROV dated on 2019-08-26: 60 Biggest Movers From Friday

Financial news for TROV dated on 2019-08-25: The Week Ahead In Biotech: A Quiet One Ahead Of Labor Day Weekend

Financial news for TROV dated on 2019-08-23: 42 Stocks Moving In Friday's Mid-Day Session

Financial news for TROV dated on 2019-08-23: 8 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for TROV dated on 2019-08-23: 33 Stocks Moving in Friday's Pre-Market Session

Financial news for TROV dated on 2019-08-22: 60 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-08-21: TrovaGene Shares Volatile Ahead of Oncology Presentation

Financial news for TROV dated on 2019-08-21: 38 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TROV dated on 2019-08-21: 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2019-08-21: 21 Stocks Moving in Wednesday's Pre-Market Session

Financial news for TROV dated on 2019-08-20: 44 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TROV dated on 2019-08-20: 22 Healthcare Stocks Moving In Tuesday's Pre-Market Session

Financial news for TROV dated on 2019-08-20: 32 Stocks Moving in Tuesday's Pre-Market Session

Financial news for TROV dated on 2019-08-20: 72 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-08-19: 48 Stocks Moving In Monday's Mid-Day Session

Financial news for TROV dated on 2019-08-19: 33 Healthcare Stocks Moving In Monday's Pre-Market Session

Financial news for TROV dated on 2019-08-19: 27 Stocks Moving in Monday's Pre-Market Session

Financial news for TROV dated on 2019-08-17: The Week Ahead In Biotech: FDA Goes Into Overdrive In A Quiet Week

Financial news for TROV dated on 2019-08-15: Trovagene To Present New Data From Onvansertib Phase 2 Study In Metastatic Castration-Resistant Prostate Cancer At Conference

Financial news for TROV dated on 2019-08-15: The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings

Financial news for TROV dated on 2019-08-14: The Daily Biotech Pulse: Regeneron's Bad Cholesterol Drug Aces Late-Stage Trial, Oncolytics Offering

Financial news for TROV dated on 2019-08-08: 50 Healthcare Stocks Moving In Thursday's After-Market Session

Financial news for TROV dated on 2019-08-08: TrovaGene Q2 EPS \$(0.79) Misses \$(0.53) Estimate, Sales \$138K Miss \$180K Estimate

Financial news for TROV dated on 2019-07-24: The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index

Financial news for TROV dated on 2019-07-23: List of Companies Reaching Yearly Lows Tuesday

Financial news for TROV dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for TROV dated on 2019-07-09: Trovagene Announces Initiation Of Enrollment For Phase 1b/2 Clinical Trial In KRAS-Mutated Colorectal Cancer At Leading Comprehensive Cancer Centers

Financial news for TROV dated on 2019-07-09: The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering

Financial news for TROV dated on 2019-07-03: The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief

Financial news for TROV dated on 2019-06-25: Trovagene Files For Mixed Shelf Offering

Financial news for TROV dated on 2019-06-21: The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

Financial news for TROV dated on 2019-05-23: Trovagene Reports Research Collab With Nektar Therapeutics To Evaluate Efficacy Of Combo Of Onvansertib, ONZEALD In Models Of Colorectal Cancer

Financial news for TROV dated on 2019-05-13: Trovagene Oncology Announces \$1.5M Investment from Lincoln Park Capital

Financial news for TROV dated on 2019-05-07: TrovaGene Q1 EPS \$(1.02) Beats \$(1.07) Estimate, Sales \$162K Miss \$170K Estimate

Financial news for TROV dated on 2019-05-03: 35 Stocks Moving In Friday's Pre-Market

Session

Financial news for TROV dated on 2019-04-25: 60 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-04-24: 50 Stocks Moving In Wednesday's Mid-Day Session

Financial news for TROV dated on 2019-04-24: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning of Wed., Apr. 24, 2019

Financial news for TROV dated on 2019-04-24: 24 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2019-04-24: 52 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-04-23: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TROV dated on 2019-04-23: Mid-Morning Market Update: Markets Open Higher; Twitter Profit Tops Views

Financial news for TROV dated on 2019-04-23: TrovaGene shares are trading higher after the company announced data demonstrating 'Significant Synergy' for its ongoing onvansertib clinical development in combination with Venetoclax.

Financial news for TROV dated on 2019-04-23: Trovogene Announces Data Demonstrating 'Significant Synergy' Of Onvansertib In Combination With Venetoclax In Cell Model Of Venetoclax-Resistant AML

Financial news for TROV dated on 2019-04-08: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for TROV dated on 2019-04-08: 54 Biggest Movers From Friday

Financial news for TROV dated on 2019-04-05: 40 Stocks Moving In Friday's Mid-Day Session

Financial news for TROV dated on 2019-04-05: Mid-Day Market Update: Crude Oil Up 1%; Aehr Test Systems Shares Spike Higher

Financial news for TROV dated on 2019-04-05: Mid-Morning Market Update: Markets Open Higher; US March Payrolls Exceed Forecasts

Financial news for TROV dated on 2019-04-05: Benzinga Pro's Top 10 Most-Searchd Tickers For Morning Of Fri., Apr. 5, 2019

Financial news for TROV dated on 2019-04-05: TrovaGene shares are trading higher after the company announced a positive data update from its Phase 1b/2 AML trial of onvansertib for patients with Acute Myeloid Leukemia.

Financial news for TROV dated on 2019-04-05: UPDATE: Trovogene Reports '~90% clinical benefit acheived - complete response + partial response + stable disease'

Financial news for TROV dated on 2019-04-05: Trovogene Offers Updated Data From Phase 1b/2 AML Trial Following AACR Meeting: 'Complete response achieved in 3 of 6 (50%) evaluable patients at the highest dose'

Financial news for TROV dated on 2019-04-05: Trovogene Reports \$1.5M Equity Investment At Premium To Market From Lincoln Park Capital

Financial news for TROV dated on 2019-04-03: 54 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-04-02: 51 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TROV dated on 2019-04-02: 32 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TROV dated on 2019-04-02: UPDATE: Trovogene Reports 'Early PSA response observed when onvansertib is added to Zytiga in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint'

Financial news for TROV dated on 2019-04-02: Trovogene Highlights Presentation Of Early Data From Ongoing Phase 2 Study Of Onvansertib In Combo With Zytiga For Patients With Metastatic Castration-Resistant Prostate Cancer

Financial news for TROV dated on 2019-04-02: 58 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-04-01: Trovogene Shares Resume Trade, Pull Back

Slightly From Highs, Stock Still Up 41.9% For Session

Financial news for TROV dated on 2019-04-01: Trovagene Shares Resume Trade, Continue Higher, Now Up 48%; Shares Halted On Second Circuit Breaker

Financial news for TROV dated on 2019-04-01: 46 Stocks Moving In Monday's Mid-Day Session

Financial news for TROV dated on 2019-04-01: UPDATE: Trovagene Sees Initial Update From Phase 2 Portion Of ProSTAR 2H'19

Financial news for TROV dated on 2019-04-01: UPDATE: Trovagene Says 'Clinical activity of CPI-1205 was seen in subsets of advanced mCRPC patients'

Financial news for TROV dated on 2019-04-01: Trovagene Highlights Presentation Of Results From Phase 1b ProSTAR Trial Of CPI-1205 At AACR Meeting

Financial news for TROV dated on 2019-04-01: 24 Stocks Moving In Monday's Pre-Market Session

Financial news for TROV dated on 2019-03-30: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

Financial news for TROV dated on 2019-03-15: 71 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-03-14: 56 Stocks Moving In Thursday's Mid-Day Session

Financial news for TROV dated on 2019-03-13: Trovagene Receives Approximately \$3M From Exercise of Warrants

Financial news for TROV dated on 2019-03-13: 56 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-03-12: 42 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TROV dated on 2019-03-12: Trovagene Regains Compliance With Nasdaq Listing Requirements

Financial news for TROV dated on 2019-03-11: 40 Stocks Moving In Monday's Mid-Day Session

Financial news for TROV dated on 2019-03-11: 30 Stocks Moving In Monday's Pre-Market Session

Financial news for TROV dated on 2019-03-11: 70 Biggest Movers From Friday

Financial news for TROV dated on 2019-03-08: Mid-Afternoon Market Update: NV5 Global Drops After Q4 Results; Seelos Therapeutics Shares Climb

Financial news for TROV dated on 2019-03-08: 50 Stocks Moving In Friday's Mid-Day Session

Financial news for TROV dated on 2019-03-08: What's Behind TrovaGene's Volatile Ride?

Financial news for TROV dated on 2019-03-08: Mid-Day Market Update: Crude Oil Down 3%; Stellar Biotechnologies Shares Surge

Financial news for TROV dated on 2019-03-08: Mid-Morning Market Update: Markets Open Lower; Big Lots Earnings Top Estimates

Financial news for TROV dated on 2019-03-08: 8 Biggest Price Target Changes For Friday

Financial news for TROV dated on 2019-03-08: 28 Stocks Moving In Friday's Pre-Market Session

Financial news for TROV dated on 2019-03-08: TrovaGene shares are trading higher on continued strength after traders on Thursday circulated word of an FDA abstract document for the company's prostate cancer treatment; analysts at Maxim and Noble Financial reiterated bullish positions on the stock.

Financial news for TROV dated on 2019-03-08: Noble Financial Reiterates Outperform on TrovaGene, Lowers Price Target from \$27 to \$20

Financial news for TROV dated on 2019-03-08: Benzinga Pro Top 10 Most-Searched Tickers For Morning Of Fri., Mar. 8, 2019

Financial news for TROV dated on 2019-03-08: 64 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-03-07: TrovaGene shares are trading higher after traders circulated word of an FDA abstract document for the company's prostate cancer treatment; Maxim reportedly reiterated an \$8 price target on the stock, citing 'positive' data on onvansertib.

Financial news for TROV dated on 2019-03-07: 51 Stocks Moving In Thursday's Mid-Day Session

Financial news for TROV dated on 2019-03-07: Maxim Reiterates \$8 Price Target On Trovogene, Sees 'Positive' Data On Onvansertib Representing A Catalyst For The Stock

Financial news for TROV dated on 2019-03-07: Trovogene Shares Spike To Session High, Now Up 17%; Traders Circulate Word Of FDA Abstract Doc For Co.'s Prostate Cancer Treatment

Financial news for TROV dated on 2019-03-06: TrovaGene Q4 EPS \$(1.09) Misses \$(1.05) Estimate, Sales \$78K Miss \$110K Estimate

Financial news for TROV dated on 2019-03-01: 75 Biggest Movers From Yesterday

Financial news for TROV dated on 2019-02-19: Trovogene Reports 1-for-6 Reverse Stock Split, Effective Feb, 19

Financial news for TROV dated on 2019-02-14: Trovogene S-3 Shows Registration For For 4M Share Common Stock Offering Via Selling Shareholders

Financial news for TROV dated on 2019-02-14: Trovogene Offers Update On Phase 2 Study Of Onvansertib In Combo With Zytiga In Patients With mCRPC at ASCO-GU Conference: 'Safety lead-in completed, no overlapping toxicities, combination is safe and well tolerated'

Financial news for TROV dated on 2019-01-29: TrovaGene shares trading higher after the company announced an agreement with PoC Capital, which will fund a trial of its Ovansertib colorectal cancer candidate; The company also announced receipt of a 'may proceed' notification from the FDA for trial.

Financial news for TROV dated on 2019-01-29: UPDATE: Trovogene Reported It Received A 'May Proceed' Notification From FDA For Phase 1b/2 Trial Of Ovansertib In Combo With Standard-Of-Care In Patients With mCRC Harboring KRAS Mutations

Financial news for TROV dated on 2019-01-29: Trovogene Reports Co., PoC Capital Entered Deal To Fund Clinical Development Of Onvansertib In Metastatic Colorectal Cancer

Financial news for TROV dated on 2019-01-23: Trovogene Announces New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer

Financial news for TROV dated on 2019-01-16: The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

Financial news for TROV dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for TROV dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for TROV dated on 2018-12-14: The Daily Biotech Pulse: Axovant In-Licenses 2 Gene Therapies, Agile To Undertake Additional Study Of Contraceptive Patch

Financial news for TROV dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for TROV dated on 2018-11-15: Trovogene Announces Nasdaq Has Granted Co.'s Request For Continued Listing On Nasdaq Capital Market, Subject To Compliance Conditions

Financial news for TROV dated on 2018-11-07: TrovaGene Q3 EPS \$(0.18) Beats \$(0.33) Estimate, Sales \$88K Miss \$100K Estimate

Financial news for TROV dated on 2018-10-24: Trovogene Announces the US Patent and Trademark Office Has Allowed Claims that Affirm Broad Coverage of NPML

Financial news for TROV dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for TROV dated on 2018-10-18: Trovogene To Offers Update On Ovansertib Clinical Development Program Wed., Oct. 24, 2018

Financial news for TROV dated on 2018-10-03: Trovagene Announces Exclusive License Agreement With MIT For Combination Therapy Of Anti-Androgens And Polo-like Kinase Inhibitors In Prostate Cancer

Financial news for TROV dated on 2018-09-27: Trovagene Reports Completion Of Dosing Cohort Of Patients Treated With Onvansertib In Combo With Decitabine In Ongoing Phase 1b/2 AML Trial

Financial news for TROV dated on 2018-09-05: Trovagene Reports It Has Developed Method For Predicting Response To Treatment By Measuring Ability Of Onvansertib To Inhibit PLK1 In Patients With Acute Myeloid Leukemia

Financial news for TROV dated on 2018-08-29: Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib

Financial news for TROV dated on 2018-08-16: Trovagene Announces Completion of Second Dosing Cohort of Patients Treated with Onvansertib

Financial news for TROV dated on 2018-08-15: Trovagene Receives USAN Approval For Onvansertib As Nonproprietary Name For First-In-Class, 3rd Generation PLK1 Inhibitor Drug Candidate, PCM-075

Financial news for TROV dated on 2018-08-03: TrovaGene Q2 EPS \$(0.44) Misses \$(0.33) Estimate, Sales \$112K Beat \$110K Estimate

Financial news for TROV dated on 2018-08-01: Trovagene Shares Down 6% Amid Positive Opinion For PCM-075 In European Union; BZ NOTE On Decline In Stock Price Following Positive News: Shares Rallied 6% Into Tues. Close Amid No News, Prior To PCM-075 News, Stock Now At Same Level As Tues. Close

Financial news for TROV dated on 2018-08-01: Trovagene Shares Up 7% Premarket As Co. Reports Received Positive Opinion For Orphan Drug Designation In European Union For PCM-075

Financial news for TROV dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for TROV dated on 2018-07-27: Benzinga's Daily Biotech Pulse: Achaogen To Trim Workforce By 28%, Amgen's Beat-And-Raise Quarter

Financial news for TROV dated on 2018-07-09: Trovagene Presents Outlook for Second Half of 2018

Financial news for TROV dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for TROV dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for TROV dated on 2018-06-27: UPDATE: Trovagene Says 'pharmacodynamic data supports inhibition of PLK1 in leukemic cells as measured by pTCTP in its Phase 1b/2 trial in Acute Myeloid Leukemia'

Financial news for TROV dated on 2018-06-27: Trovagene Reports Prelim. Data From First Dosing Cohort Showing Durable Treatment Effect Of PCM-075 In Combo with Cytarabine Or Decitabine In Patients With Relapsed Or Refractory AML

Financial news for TROV dated on 2018-06-25: A Peek Into The Markets: US Stock Futures Drop, Dow Futures Down Over 150 Points

Financial news for TROV dated on 2018-06-25: 6 Stocks To Watch For June 25, 2018

Financial news for TROV dated on 2018-06-22: Trovagene CEO William Welch Steps Down For Personal Reasons, Effective Immediately, Dr. Thomas Adams Will Serve In The Interim As A Search Is Conducted

Financial news for TROV dated on 2018-06-21: Trovagene Reports the Start of Recruitment, Enrollment for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga

Financial news for TROV dated on 2018-06-15: Maxim Group Upgrades TrovaGene to Buy

Financial news for TROV dated on 2018-06-15: UPDATE: Trovagene Highlights Safety Review Committee Has Recommended Proceeding To Second Dosing Cohort In PCM-075 Combo Trial

Financial news for TROV dated on 2018-06-15: Trovagene Reports Completion Of First Dosing Cohort Of Patients Treated With PCM-075 In Combo With Decitabine In Ongoing

Phase 1b/2 AML Trial

Financial news for TROV dated on 2018-06-08: Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs

Financial news for TROV dated on 2018-06-08: Trovogene Prices 18M Share Public Offering of Stocks and Warrants @\$1.00/Share and Warrant

Financial news for TROV dated on 2018-06-07: Benzinga's Daily Biotech Pulse: Johnson & Johnson to Dispose Sterilization Products Business, Mixed Results From Protesostasis' Cystic Fibrosis Study

Financial news for TROV dated on 2018-06-07: 40 Biggest Movers From Yesterday

Financial news for TROV dated on 2018-06-06: Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

Financial news for TROV dated on 2018-06-06: 45 Biggest Movers From Yesterday

Financial news for TROV dated on 2018-06-05: 35 Stocks Moving In Tuesday's Mid-Day Session

Financial news for TROV dated on 2018-06-04: Benzinga Pro's Top 10 Most-Searchd Tickers For The Evening Of Mon., Jun. 4

Financial news for TROV dated on 2018-05-31: Trovogene, Inc. Announces 1-for-12 Reverse Stock Split Effective June 1

Financial news for TROV dated on 2018-05-08: TrovaGene Q1 EPS \$(0.09) Beats \$(0.12) Estimate, Sales Met \$100K Estimate

Financial news for TROV dated on 2018-04-16: Trovogene Reports PCM-075 Combo With Quizartinib Resulted In 97% Tumor Growth Inhibition, Regression In FLT3 AML Model; Data Presented At AACR Meeting

Financial news for TROV dated on 2018-03-13: Trovogene Shares Spike Over \$0.40 Level, Now Up 15% For Session; Not Seeing Mid-Day News To Justify Price Action

Financial news for TROV dated on 2018-03-05: Trovogene Shares Up 16.2% Premarket After Co. Announced First Patient Successfully Completed Cycle 1 Of Treatment With PCM-075

Financial news for TROV dated on 2018-03-05: Trovogene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial

Financial news for TROV dated on 2018-02-26: Trovogene Reports Q4 EPS \$(0.06) vs \$(0.34) In Same Qtr. Last Year, Sales \$185K vs \$68K YoY

Financial news for TROV dated on 2018-02-13: UPDATE: Trovogene Says 'Yale Cancer Center and Kansas University Cancer Center now actively screening and enrolling patients in Phase 1b/2 Study of PCM-075 in AML

Financial news for TROV dated on 2018-02-13: Trovogene Reports Activation Of 2 Added Clinical Trial Sites To Conduct Its Phase 1b/2 Study Of PCM-075 In Patients With AML

Financial news for TROV dated on 2018-02-12: TrovaGene Shares Down 8.3% On Potential Profit Taking; Friday Shares Rose As Much As 37% After Encouraging Presentation of Data For PCM-075

Financial news for TROV dated on 2018-02-12: 44 Biggest Movers From Friday

Financial news for TROV dated on 2018-02-09: Trovogene Presents Data Showing Synergy of PCM-075 in Combination with Zytiga(r) in Castration-Resistant Prostate Cancer Model at 2018 Genitourinary Cancers Symposium

Financial news for TROV dated on 2018-01-24: Trovogene Initiates UNITE Phase 2 Trial Of PCM-075 In Patients With mCRPC

Financial news for TROV dated on 2017-12-21: Benzinga's Top Upgrades, Downgrades For December 21, 2017

Financial news for TROV dated on 2017-12-21: Trovogene Reports Activation Of Second Trial Site In Phase 1b/2 AML Trial For PCM-075

Financial news for TROV dated on 2017-12-18: 33 Biggest Movers From Friday

Financial news for TROV dated on 2017-12-15: Mid-Afternoon Market Update: Dow Surges Over 150 Points; Longfin Shares Spike Higher

Financial news for TROV dated on 2017-12-15: 30 Stocks Moving In Friday's Mid-Day Session

Financial news for TROV dated on 2017-12-15: Mid-Day Market Update: ShiftPixy Gains Following Q4 Results; Verastem Shares Plummet

Financial news for TROV dated on 2017-12-15: Mid-Morning Market Update: Markets Open Higher; Adobe Earnings Top Expectations

Financial news for TROV dated on 2017-12-15: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for TROV dated on 2017-12-15: Trovogene Prices 15M Share Common Stock Offering At \$0.30/Share

Financial news for TROV dated on 2017-12-14: Trovogene Submits Protocol to FDA for Phase 2 Clinical Trial of PCM-075 in Combination with Zytiga

Financial news for TROV dated on 2017-12-07: Trovogene Shares Indicated Higher After Hours Thurs. As Co. Issues Release Highlighting Data In SABCS 'Showing Sensitivity Of Triple Negative Breast Cancer Cell Lines To PCM-075, Synergy with Zytiga'

Financial news for TROV dated on 2017-11-10: Maxim Group Downgrades TrovaGene to Hold

Financial news for TROV dated on 2017-11-09: Trovogene Issues Release Highlighting Earlier-Issued (Via 8-K) Q3 Results: EPS \$(0.12) vs \$(0.14) Est., Sales \$123K vs \$89K In Same Qtr. Last Year

Financial news for TROV dated on 2017-10-25: Trovogene S-1 Filing Shows Registration For \$17.5M Mixed Securities Shelf Offering

Financial news for TROV dated on 2017-10-18: Trovogene Reports Data From Preclinical Research Demonstrating Synergy Of PCM-075 With Zytiga

Financial news for TROV dated on 2017-10-12: Secondary Offering Lockup Expirations Today For Westport Fuel Systems and TrovaGene

Financial news for TROV dated on 2017-10-09: Trovogene Reports FDA Orphan Drug Designation For PCM-075 For Treatment Of AML

Financial news for TROV dated on 2017-09-27: Secondary Offering Lockup Expirations For Akebia Therapeutics and Trovogene

Financial news for TROV dated on 2017-08-16: Trovogene Reports PLK1 Inhibitor PCM-075 Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy

Financial news for TROV dated on 2017-08-09: Trovogene Reports Q2 EPS \$(0.26) vs \$(0.15) Est., Sales \$102K vs \$104K In Same Qtr. Last Year

Financial news for TROV dated on 2017-07-27: Trovogene Reports FDA Approval Of IND For Phase 1b/2 Trial Of PCM-075 In Patients With AML

Financial news for TROV dated on 2017-07-27: Trovogene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia

Financial news for TROV dated on 2017-07-25: Trovogene Reports Peer-Reviewed Publication of First-in-Human Phase 1 Trial Results with PCM-075

Financial news for TROV dated on 2017-07-24: CVI Investments Shows a 5.7% Passive Stake in Trovogene

Financial news for TROV dated on 2017-07-17: 13G Filing From Sabby Mgmt. On Trovogene Shows New 5.7% Stake

Financial news for TROV dated on 2017-07-14: Trovogene Reports \$7.1M Registered Direct Offering

Financial news for TROV dated on 2017-07-06: Trovogene Reports Engaged The Leading Global Contract Research Organization To Conduct Phase 1b/2 Trial Of PCM-075

Financial news for TROV dated on 2017-06-29: Trovogene Reports Deal With NerPharMa For Supply Of PCM-075 For AML Trial

Financial news for TROV dated on 2017-06-28: Trovogene Shares Up 13.5% No New News Wed.; Co. Announced 2 News Items Over Last 2 Days: Submission Of IND For FDA Approval Of PCM-075, Expansion Of Claims For NPM1 Patent Portfolio

Financial news for TROV dated on 2017-06-27: Trovogene Reports Submission Of IND

Application To Initiate Phase 1b/2 Trial Of PCM-075 For Acute Myeloid Leukemia

Financial news for TROV dated on 2017-06-26: Trovagene Reports Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia

Financial news for TROV dated on 2017-06-22: Trovagene Shares Volatile After Hours, Indicated Up ~4%; Likely Trading In Sympathy With Idera, Up 14% On FDA Orphan Drug News

Financial news for TROV dated on 2017-06-22: Trovagene Reports Agreement With Undisclosed Biopharmaceutical Company To Utilize Trovera ctDNA Tests, Services In Cancer Clinical Trials

Financial news for TROV dated on 2017-06-12: Mid-Afternoon Market Update: Coherus Biosciences Drops After FDA Response Letter; TrovaGene Shares Surge

Financial news for TROV dated on 2017-06-12: 15 Biggest Mid-Day Gainers For Monday

Financial news for TROV dated on 2017-06-12: Mid-Day Market Update: Crude Oil Up 1%; GTx Shares Spike Higher

Financial news for TROV dated on 2017-06-12: Mid-Morning Market Update: Markets Open Lower; General Electric CEO To Step Down

Financial news for TROV dated on 2017-06-12: Trovagene Reports Deal With AstraZeneca For Utilization Of Trovera ctDNA Test, Services In Prospective Biomarker Study

Financial news for TROV dated on 2017-05-25: Trovagene Phase 1 Safety Supports Planned Development of PCM-075 In AML

Financial news for TROV dated on 2017-05-10: Trovagene Reports Q1 EPS \$(0.32) vs \$(0.24) Est., Sales \$95K vs \$120K In Prior Year Period

Financial news for TROV dated on 2017-04-12: Shares of Trovagene Up 13%, Hearing Maxim Upgrades Trovagene To Buy

Financial news for TROV dated on 2017-03-22: 15 Biggest Mid-Day Losers For Wednesday

Financial news for TROV dated on 2017-03-16: Mid-Afternoon Market Update: Oracle Gains On Earnings Beat; TrovaGene Shares Slide

Financial news for TROV dated on 2017-03-16: 18 Biggest Mid-Day Losers For Thursday

Financial news for TROV dated on 2017-03-16: Mid-Day Market Update: U.S. Stocks Turn Negative; GoPro Shares Spike Higher

Financial news for TROV dated on 2017-03-16: Mid-Morning Market Update: Markets Open Higher; Dollar General Beats Q4 Expectations

Financial news for TROV dated on 2017-03-16: PiperJaffray Downgrades TrovaGene To Underweight

Financial news for TROV dated on 2017-03-15: Trovagene Reports Q4 EPS \$(0.34) vs. \$(0.32) Est., Sales \$68K vs. \$180K Est.

Financial news for TROV dated on 2017-03-15: Trovagene & Nerviano Announce License Agreement For Therapeutic Candidate PCM-075

Financial news for TROV dated on 2017-01-24: Trovagene Reports Publication of Trovera KRAS Liquid Biopsy Test Showed Clinical Utility in Advanced Cancers for Detection and Measurement of Therapeutic Response

Financial news for TROV dated on 2016-12-14: 18 Biggest Mid-Day Losers For Wednesday

Financial news for TROV dated on 2016-12-14: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for TROV dated on 2016-12-13: UPDATE: Trovagene Says Will Increase Focus on Global Distribution of Kits, Systems to Clinical Research Labs for Liquid Biopsy Oncology Testing Market

Financial news for TROV dated on 2016-12-13: Trovagene Reports Reorganization

Financial news for TROV dated on 2016-11-30: Trovagene and Boreal Genomics Announce Strategic Partnership

Financial news for TROV dated on 2016-11-15: Trovagene, Inc.: MIGNONE ROBERTO (10%+) Buys 322,472 @ Avg Price: \$3.08 (Form4

Financial news for TROV dated on 2016-11-09: Trovogene Reports Q3 EPS \$(0.34) vs \$(0.29) Est.

Financial news for TROV dated on 2016-11-07: Trovogene Announces U.S. Patent and Trademark Office has Issued Patent No 9,453,265 Entitled 'Method for Detection of High Risk Human Papillomavirus'

Financial news for TROV dated on 2016-10-04: Trovogene Selected by Pancreatic Cancer Action Network as Liquid Biopsy Provider to Participate in Precision Promise

Financial news for TROV dated on 2016-09-26: Trovogene Releases Investor Presentation

Financial news for TROV dated on 2016-08-17: Maxim Issues Mid-Day Note on Trovogene: 'We continue to see Trovogene as the go-to company in detection'

Financial news for TROV dated on 2016-08-17: Trovogene Reports BCBS Illinois Will Cover Trovera Liquid Biopsy Tests

Financial news for TROV dated on 2016-08-08: 8 Biggest Price Target Changes For Monday

Financial news for TROV dated on 2016-08-08: Cantor Fitzgerald Upgrades Trovogene To Buy, Bullish On Clinical Business

Financial news for TROV dated on 2016-08-08: Cantor Fitzgerald Upgrades TrovaGene to Buy

Financial news for TROV dated on 2016-08-04: Trovogene Reports Q2 EPS \$(0.34) vs \$(0.31) Est., Sales \$104K vs \$270K Est.

Financial news for TROV dated on 2016-07-12: Trovogene, USC Norris Comprehensive Cancer Center Partner For Standard Use Of Trovera ctDNA Liquid Biopsy Tests In Patient Care

Financial news for TROV dated on 2016-07-06: Trovogene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer

Financial news for TROV dated on 2016-06-06: Trovogene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer

Financial news for TROV dated on 2016-05-27: Trovogene Files for Up to \$250M Mixed Shelf

Financial news for TROV dated on 2016-05-18: 8-K from Trovogene Shows William Welch Named CEO

Financial news for TROV dated on 2016-05-13: Mid-Afternoon Market Update: Dow Tumbles 1%; Nordstrom Shares Down Following Earnings Miss

Financial news for TROV dated on 2016-05-13: Trovogene Announces Large Clinical Study Shows High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients

Financial news for TROV dated on 2016-05-10: Trovogene Reports Q1 EPS \$(0.36) vs. Est. \$(0.29), Rev. \$120K vs. Est. \$260K

Financial news for TROV dated on 2016-04-27: Antonius Schuh Resigns as Member of Trovogene Board of Directors

Financial news for TROV dated on 2016-04-26: Cantor Fitzgerald Downgrades TrovaGene to Hold

Financial news for TROV dated on 2016-04-26: Leerink Swann Downgrades TrovaGene to Sector Perform

Financial news for TROV dated on 2016-04-25: Departure Of TrovaGene CCO Creates Near-Term Risks; Cantor Downgrades Stock

Financial news for TROV dated on 2016-04-25: Mid-Afternoon Market Update: Crude Oil Down 2%; KKR Shares Slide Following Q1 Results

Financial news for TROV dated on 2016-04-25: Mid-Day Market Update: Tribune Publishing Jumps Following Gannett's Takeover Proposal; TrovaGene Shares Drop

Financial news for TROV dated on 2016-04-25: Cantor Fitzgerald Says New CEO A Positive, But CCO Departure Creates Near-Term Risks Downgrades Trovogene To Hold With \$5 Price Target

Financial news for TROV dated on 2016-04-25: Hearing Cantor Fitzgerald Downgrades

TrovaGene to Hold in Mid-Day Note

Financial news for TROV dated on 2016-04-25: Mid-Morning Market Update: Markets Open Lower; Xerox Profit Misses Views

Financial news for TROV dated on 2016-04-25: Trovagene Names Bill Welch as CEO

Financial news for TROV dated on 2016-04-15: Trovagene Gains 3% On Favorable Mention In Medical Journal

Financial news for TROV dated on 2016-04-15: Trovagene Announces Patient Case Report Usings Precision Cancer Monitoring Technology

Financial news for TROV dated on 2016-04-11: TrovaGene Stikes A Preferred Provider Deal With Stratose

Financial news for TROV dated on 2016-04-11: Trovagene Reports Entered Into Preferred Provider Deal with Stratose PPO Network

Financial news for TROV dated on 2016-04-07: TrovaGene To Present Clinical Data On Its Precision Cancer Monitoring Platform

Financial news for TROV dated on 2016-04-07: Trovagene Announces Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference

Financial news for TROV dated on 2016-04-05: Bridger Management, LLC Reports 11% Stake in Trovagene in 13D

Financial news for TROV dated on 2016-03-29: 10 Stocks Moving In Tuesday's Pre-Market Session

Financial news for TROV dated on 2016-03-29: TrovaGene Down 40% Following Termination Of CEO, CFO

Financial news for TROV dated on 2016-03-29: Avondale Partners Maintains Market Perform on TrovaGeneto Market Perform, Removes \$6.00 PT Citing Lack of Visibility For Co In Lieu Of CEO/CFO Departure

Financial news for TROV dated on 2016-03-28: Trovogene Shares Fall 50% After Hours Following Announcement of Termination of CEO, CFO

Financial news for TROV dated on 2016-03-28: UPDATE: Trovagene Alleges Schuh, Zaniboni Used Promising New Therapeutics in the Field of Precision Medicine for their own Personal Benefit

Financial news for TROV dated on 2016-03-28: Trovagene Terminates Employment of CEO Antonius Schuh, CFO Stephen Zaniboni for Cause

Financial news for TROV dated on 2016-03-11: Mid-Afternoon Market Update: Dow Jumps 200 Points; Bojangles Shares Climb Following Upbeat Earnings

Financial news for TROV dated on 2016-03-11: Mid-Day Market Update: Finisar Gains On Earnings Beat; FXCM Shares Drop

Financial news for TROV dated on 2016-03-11: Mid-Morning Market Update: Markets Open Higher; Hibbett Sports Q4 Earnings Top Expectations

Financial news for TROV dated on 2016-03-11: Janney Capital Downgrades TrovaGene to Neutral

Financial news for TROV dated on 2016-03-10: Trovagene Reports Q4 EPS \$(0.26) vs. Est. \$(0.25)

Financial news for TROV dated on 2016-03-04: Trovagene Spikes to High of \$6.66 on Volume

Financial news for TROV dated on 2016-03-01: Trovagene Enters Into Preferred Provider Agreement with Multiplan, Inc.

Financial news for TROV dated on 2016-02-22: Trovagene Announces Entered Into Preferred Provider Deal with Fortified Provider Network

Financial news for TROV dated on 2016-02-09: Trovagene Spikes to High of \$3.97 on Volume

Financial news for TROV dated on 2016-02-01: Here's Why Shares Of TrovaGene Are Surging

Financial news for TROV dated on 2016-02-01: Trovogene Announces Agreement with FedMed

Financial news for TROV dated on 2016-01-27: Option Alert: TROV Jul16 2.5 Calls Sweep: 500 @ ASK \$1.90: 500 traded vs 242 OI: Earnings 3/10 \$3.91 Ref

Financial news for TROV dated on 2016-01-21: Spike in Trovogene May Attributed to Tweet from Co

Financial news for TROV dated on 2016-01-21: Trovogene Spikes to High on Volume

Financial news for TROV dated on 2016-01-06: Avondale Partners Initiates Coverage on TrovaGene at Market Perform, Announces \$6.00 PT

Financial news for TROV dated on 2015-12-22: Mid-Afternoon Market Update: Dow Jumps Over 150 Points; Steelcase Shares Dip Following Weak Results

Financial news for TROV dated on 2015-11-17: Option Alert: \$TROV Jan \$7.5 Call; 628 Contracts @\$0.45

Financial news for TROV dated on 2015-11-09: Trovogene Reports Q3 EPS \$(0.23) vs. Est. \$(0.27)

Financial news for TROV dated on 2015-10-27: Trovogene's Urine-Based Liquid Biopsy Platform Shows Clinical Sensitivity of 93 Percent in Lung Cancer Study

Financial news for TROV dated on 2015-10-08: Practical Clinical Benefits of Trovogene's Urine-Based Liquid Biopsy Platform Shown in Field Experience Analysis

Financial news for TROV dated on 2015-09-21: Trovogene Offers Results from Second Large-Scale Trial of Urine-Based HPV Test: Results Compared to Roche's cobas HPV Test

Financial news for TROV dated on 2015-09-16: Cantor Says Trovogene's Liquid Biopsies Have '10x The Kick,' Is Buying In

Financial news for TROV dated on 2015-09-15: Cantor Fitzgerald Initiates Coverage on TrovaGene at Buy, Announces \$10.00 PT

Financial news for TROV dated on 2015-09-10: Trovogene Forms European Subsidiary Trovogene Research Institute

Financial news for TROV dated on 2015-09-09: Trovogene's Urine-Based Liquid Biopsy Platform Shown to Detect Impact of Cancer Therapy within 24 Hours

Financial news for TROV dated on 2015-08-18: Trovogene to Present Clinical Data and Capabilities of Its Urine-Based Liquid Biopsy Platform at the 7th Annual Next Generation Dx Summit

Financial news for TROV dated on 2015-08-14: Benzinga's Top Initiations

Financial news for TROV dated on 2015-08-14: Leerink: Trovogene Is A Pure Play That Should Outperform

Financial news for TROV dated on 2015-08-14: Leerink Swann Initiates Coverage on TrovaGene at Outperform, Announces \$9.00 PT

Financial news for TROV dated on 2015-08-12: Trovogene CFO Zaniboni Buys 15,000 Shares @\$5.43/Share -Form 4

Financial news for TROV dated on 2015-08-10: Trovogene Reports Q2 EPS \$(0.41) vs. Est. \$(0.24)

Financial news for TROV dated on 2015-07-17: Market Update: Google & Hertz Among Mid-Day Movers, Germany Votes In Favor Of Greece Bailout And More

Financial news for TROV dated on 2015-07-17: Morning Market Losers

Financial news for TROV dated on 2015-07-17: Trovogene Prices Offering of 4M Shares At \$8.75/Share

Financial news for TROV dated on 2015-07-17: Trovogene Inc Reports Public Offering Of 4 Million Shares Of Common Stock; Gross Proceeds Expected To Be \$35M

Financial news for TROV dated on 2015-07-16: Trovogene Reports Proposed Offering

Financial news for TROV dated on 2015-07-08: Trovogene Begins Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform

Financial news for TROV dated on 2015-06-08: Trovogene to Offer Clinical Data on Co.'s Urine-Based Liquid Biopsy Platform at Two Upcoming Conferences

Financial news for TROV dated on 2015-05-01: Trovogene Trading Resumed

Financial news for TROV dated on 2015-05-01: Trovogene Trading Halted

Financial news for TROV dated on 2015-05-01: Trovogene Shares Spike Higher; Hearing Positive Altucher Comments

Financial news for TROV dated on 2015-04-20: Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research

Financial news for TROV dated on 2015-04-17: UPDATE: Trovogene Shares Rise 23% Following Announcement of Positive Data for Urine-based Precision Cancer Monitoring Platform

Financial news for TROV dated on 2015-04-02: Janney Capital Initiates Coverage on TrovaGene at Buy, Announces \$11.00 PT

Financial news for TROV dated on 2015-03-20: 9 Management Changes From The Past Week

Financial news for TROV dated on 2015-03-18: Stocks Hitting 52-Week Highs

Financial news for TROV dated on 2015-03-18: Trovogene Names Matthew Posard Chief Commercial Officer

Financial news for TROV dated on 2015-03-12: Trovogene Reports Q4 EPS \$(0.25) vs. Est. (\$0.26)

Financial news for TROV dated on 2015-02-17: Piper Jaffray Initiates Coverage on TrovaGene at Overweight, Announces \$6.25 PT

Financial news for TROV dated on 2015-02-09: TrovaGene Announces Clinical Results Show High Sensitivity of Urine-Based HPV Assay for Detection of High Risk HPV

Financial news for TROV dated on 2015-02-06: TrovaGene Falls Sharply; Prices Offering Below Expectations

Financial news for TROV dated on 2015-02-06: Friday Morning Movers: GoPro, Twitter Move In Opposite Directions

Financial news for TROV dated on 2015-02-06: Morning Market Losers

Financial news for TROV dated on 2015-02-06: Trovogene Announces Pricing of \$20M Public Offering of Common Stock

Financial news for TROV dated on 2015-02-05: Trovogene Announces Public Offering of Common Stock

Financial news for TROV dated on 2015-01-20: Clinical Study Results Presented at the 2015 Gastrointestinal Cancer Symposium Support Utility of Trovogene's Precision Cancer Monitoring Platform in Colorectal and Pancreatic Cancer Patients

Financial news for TROV dated on 2014-11-20: Trovogene Releases Clinical Study Results For The Detection And Monitoring Of KRAS Mutations

Financial news for TROV dated on 2014-08-18: Trovogene IR Says No News to Account for Move in Share Price Today, Attributes to Buyer of Co's Stock

Financial news for TROV dated on 2014-08-18: Morning Market Movers

Financial news for TROV dated on 2014-07-09: Maxim Group Initiates Coverage on TrovaGene, Inc. at Buy, Announces \$10.00 PT

Financial news for TROV dated on 2014-07-01: Trovogene Secures \$15 Million in Debt Financing From Silicon Valley Bank And Oxford Finance

Financial news for TROV dated on 2014-06-02: Corporate Events for the Week of Jun. 2nd, 2014

Financial news for TROV dated on 2014-06-02: Trovogene Announces Positive Results From Oncogen Mutation

Financial news for TROV dated on 2014-01-06: Trovogene, US Oncology Research Announce Clinical Study Agreement

Financial news for TROV dated on 2013-11-15: Aegis Capital Reiterates on TrovaGene

Following In-Line Revenue, Below-Estimates EPS

Financial news for TROV dated on 2013-11-14: TrovaGene, Inc. Reports Q3 EPS of \$(0.25) vs \$(0.22) Est; Revenue of \$44.0K vs \$470.0K Est

Financial news for TROV dated on 2013-11-13: UPDATE: Aegis Capital Reiterates on TrovaGene Ahead of 3Q 2013 Earnings Report

Financial news for TROV dated on 2013-10-31: James Altucher Update on Post in Seeking Alpha: 'Trovagene: The 1 Stock That Could've Saved Steve Jobs' Life'

Financial news for TROV dated on 2013-10-16: Trovagene Announces Collaboration for Oncogene Mutation Detection Study

Financial news for TROV dated on 2013-10-14: Trovagene Abstracts to be Presented at Molecular Targets and Cancer Therapeutics Conference

Financial news for TROV dated on 2013-09-25: Trovagene Awarded NPM Patent

Financial news for TROV dated on 2013-08-30: Market Wrap for Friday, August 30, 2013: Summer Ending in Turmoil?

Financial news for TROV dated on 2013-08-14: TrovaGene, Inc. Reports Q2 EPS of \$(0.30) Which May Not Compare \$(0.15) Est

Financial news for TROV dated on 2013-07-24: Trovagene Receives Broad MicroRNA Patent

Financial news for TROV dated on 2013-07-22: Trovagene Urine-based Cancer Detection Technology Validated

Financial news for TROV dated on 2013-07-16: UPDATE: Cantor Fitzgerald Initiates Trovagene at Buy on Unique Technology Platform

Financial news for TROV dated on 2013-07-16: Cantor Fitzgerald Initiates Coverage on TrovaGene, Inc. at Buy, Announces \$10.00 PT

Financial news for TROV dated on 2012-12-20: From Earlier: Roth Capital Initiates Coverage on TrovaGene, Inc. at Buy, Announces \$11.00 PT

Financial news for TROV dated on 2012-12-12: Aegis Evaluates Chinese Bio Firms

Financial news for TROV dated on 2012-12-12: UPDATE: Aegis Capital Initiates Coverage on TrovaGene with Buy Rating, \$12 PT

Financial news for TROV dated on 2012-12-12: Aegis Capital Initiates Coverage on TrovaGene, Inc. at Buy, Announces \$12.00 PT

Financial news for TROV dated on 2012-11-28: Trovagene Announces Urine-Based Molecular Diagnostic Test for Transrenal Cancer Mutation Monitoring

Financial news for TROV dated on 2012-09-20: Trovagene and Strand Life Sciences Sign Agreement for Urine-Based HPV Test in India and South Asia

Financial news for TROV dated on 2012-08-29: A Peek Into The Market Before The Trading Starts

Financial news for TROV dated on 2012-08-29: Trovagene, Inc., Achieves Intellectual Property Milestone under License Agreement with Ipsogen

Financial news for TROV dated on 2012-07-23: TrovaGene Halted on Circuit-Breaker

Financial news for TROV dated on 2012-07-18: Trovagene, Inc., Announces Issuance of U.S. Patent for NPM Mutants to Diagnose and Monitor Acute Myeloid Leukemia

Financial news for TROV dated on 2012-06-13: Trovagene, Inc. Announces Full Exercise of Over-Allotment Option by Aegis Capital Corp.